- Made Scientific has established its first Scientific Advisory Board (SAB) with four appointments.
- The SAB will provide strategic guidance to advance cell therapy manufacturing, testing, and accessibility.
Made Scientific, a U.S.-based contract development and manufacturing organisation (CDMO) specialising in cell therapies, has announced the creation of its first Scientific Advisory Board (SAB). The board comprises Miguel Forte, M.D., Ph.D., Paul K. Wotton, Ph.D., Shishir Gadam, Ph.D., and Young K. Hong, M.D.
The SAB will support the company’s goal of redefining cell therapy manufacturing and testing. By bringing together leaders from product translation, bioprocess and analytical technologies, and regulatory and clinical practice, the board will offer expertise to strengthen Made’s CDMO platform and accelerate innovation. Their input will focus on reducing the cost of goods for cell therapies and enabling partners to deliver more accessible treatments worldwide.
“The establishment of our Scientific Advisory Board marks a pivotal moment in our commitment to innovation,” said Syed T. Husain, Chairman and CEO of Made Scientific. “Miguel, Paul, Shishir, and Young each bring world-class expertise across cell therapy, manufacturing science, commercialisation, and clinical practice. Their guidance will directly shape our service priorities, ensuring we deliver advanced, accessible, and scalable solutions for patients globally.”
The new members bring backgrounds spanning leadership at biotech firms, regulatory agencies, and academic institutions. Their combined expertise covers cell and gene therapy development, manufacturing infrastructure, clinical applications, and commercialisation.
